Literature DB >> 17728787

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.

G Barosi, R A Mesa, J Thiele, F Cervantes, P J Campbell, S Verstovsek, B Dupriez, R L Levine, F Passamonti, J Gotlib, J T Reilly, A M Vannucchi, C A Hanson, L A Solberg, A Orazi, A Tefferi.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17728787     DOI： 10.1038/sj.leu.2404914

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  134 in total

Review 1.  Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis.

Authors:  Vikas Gupta; Jason Gotlib; Jerald P Radich; Nicolaus M Kröger; Damiano Rondelli; Srdan Verstovsek; H Joachim Deeg
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-27       Impact factor: 5.742

2.  JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis.

Authors:  Paola Guglielmelli; Giovanni Barosi; Lisa Pieri; Elisabetta Antonioli; Alberto Bosi; Alessandro M Vannucchi
Journal:  Haematologica       Date:  2008-11-27       Impact factor: 9.941

3.  Myelofibrotic transformation in essential thrombocythemia.

Authors:  Juergen Thiele; Hans Michael Kvasnicka
Journal:  Haematologica       Date:  2009-01-30       Impact factor: 9.941

Review 4.  WHO classification of myeloproliferative neoplasms (MPN): A critical update.

Authors:  Hans Michael Kvasnicka
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

5.  The relationship between serum ferritin level and fibrosis and splenomegaly in myelofibrosis.

Authors:  Osman Yokus; Betul Yigit; Hasan Goze; Istemi Serin
Journal:  Am J Blood Res       Date:  2020-12-15

Review 6.  Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.

Authors:  Rachel B Salit; H Joachim Deeg
Journal:  Hematol Oncol Clin North Am       Date:  2014-10-03       Impact factor: 3.722

7.  Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Authors:  Fabio P S Santos; Hagop M Kantarjian; Nitin Jain; Taghi Manshouri; Deborah A Thomas; Guillermo Garcia-Manero; Debra Kennedy; Zeev Estrov; Jorge Cortes; Srdan Verstovsek
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

8.  Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis.

Authors:  Marko Lucijanic; Davor Galusic; Ivan Krecak; Martina Sedinic; Hrvoje Holik; Vlatka Perisa; Martina Moric Peric; Ivan Zekanovic; Tajana Stoos-Veic; Rajko Kusec
Journal:  Ann Hematol       Date:  2020-08-29       Impact factor: 3.673

9.  Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years.

Authors:  Rakhee Vaidya; Sergio Siragusa; Jocelin Huang; Susan M Schwager; Curtis A Hanson; Kebede Hussein; Animesh Pardanani; Ayalew Tefferi
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

10.  Ruxolitinib: in the treatment of myelofibrosis.

Authors:  Lily P H Yang; Gillian M Keating
Journal:  Drugs       Date:  2012-11-12       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.